{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:22:53Z","timestamp":1784762573371,"version":"3.55.0"},"reference-count":25,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Swiss Association of Public Health Administration and Hospital Pharmacists","award":["GSASA"],"award-info":[{"award-number":["GSASA"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background\/Objectives: Parenteral antibiotic therapy is indispensable in the treatment of several infections. The parenteral administration often leads to the need for prolonged hospitalization. Therefore, interest in outpatient parenteral antimicrobial therapy (OPAT) is growing. OPAT is typically administered in elastomeric devices, which release an infusion solution over a 24 h period and are meanwhile worn close to the body. This work aimed to evaluate the stability of the reserve antibiotics ceftazidime-avibactam and ceftolozane-tazobactam for OPAT use. Methods: Elastomeric pumps were prepared in triplicate at the dosages 3.75 and 7.5 g of ceftazidime-avibactam and 2.25, 4.5, and 9.0 g of ceftolozane-tazobactam in 240 mL 0.9% saline each. The pumps were first stored at 2\u20138 \u00b0C for 7 days and subsequently incubated for 48 h at 25 \u00b0C. To determine actual concentrations of ceftazidime, avibactam, ceftolozane, tazobactam, and pyridine, samples were taken at nine different time points during storage and incubation. High-performance liquid chromatography coupled to tandem mass spectrometry was used for quantification. Results: Although concentrations of ceftazidime and avibactam stayed above 90% during a 24 h incubation period at 25 \u00b0C, the pyridine limit of the European Pharmacopeia was already exceeded in the ceftazidime-avibactam pumps after the storage time at 2\u20138 \u00b0C. In the ceftolozane-tazobactam pumps, the ceftolozane concentration was stable for 24 h incubation, but tazobactam concentrations decreased below 90% within 12 h in the two higher dosages. Conclusions: Accordingly, stability cannot be guaranteed for both tested preparations and their use for OPAT should be thoroughly considered.<\/jats:p>","DOI":"10.3390\/antibiotics14100966","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:48:05Z","timestamp":1758808085000},"page":"966","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Stability of Two Reserve Antibiotics in Elastomeric Pumps: Ceftazidime-Avibactam and Ceftolozane-Tazobactam"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0832-8743","authenticated-orcid":false,"given":"Joana","family":"Erdmann","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, University Hospital Basel, 4031 Basel, Switzerland"},{"name":"Department of Pharmaceutical Sciences, University of Basel, 4001 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8843-5197","authenticated-orcid":false,"given":"Linh Anna Tr\u00fac","family":"Vu","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy, University Hospital Basel, 4031 Basel, Switzerland"},{"name":"Department of Experimental and Clinical Pharmacology and Pharmacogenomics, University Hospital T\u00fcbingen, 72076 T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9630-6597","authenticated-orcid":false,"given":"Delia","family":"Halbeisen","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Basel, 4001 Basel, Switzerland"},{"name":"Hospital Pharmacy, University Hospital Basel, 4031 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6585-9778","authenticated-orcid":false,"given":"Katharina M.","family":"Rentsch","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University Hospital Basel, 4031 Basel, Switzerland"},{"name":"Faculty of Medicine, University of Basel, 4001 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/Avibactam and Ceftolozane\/Tazobactam: Second-generation beta-Lactam\/beta-Lactamase Inhibitor Combinations","volume":"63","author":"Bonomo","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: A Position Paper","volume":"46","author":"Alffenaar","year":"2020","journal-title":"Intensive Care Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s15010-019-01381-8","article-title":"OPAT in Switzerland: Single-center experience of a model to treat complicated infections","volume":"48","author":"Erba","year":"2020","journal-title":"Infection"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s15010-024-02194-0","article-title":"Improving antimicrobial treatment in terms of antimicrobial stewardship and health costs by an OPAT service","volume":"52","author":"Burch","year":"2024","journal-title":"Infection"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/17843286.2019.1608396","article-title":"Clinical characteristics and outcomes of patients receiving outpatient parenteral antibiotic therapy in a Belgian setting: A single-center pilot study","volume":"75","author":"Briquet","year":"2020","journal-title":"Acta Clin. Belg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/jac\/dks003","article-title":"Good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults in the UK: A consensus statement","volume":"67","author":"Chapman","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/jac\/dkw582","article-title":"Antibiotic stability related to temperature variations in elastomeric pumps used for outpatient parenteral antimicrobial therapy (OPAT)","volume":"72","author":"Voumard","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Loeuille, G., D\u2019Huart, E., Vigneron, J., Nisse, Y.E., Beiler, B., Polo, C., Ayari, G., Sacrez, M., Demore, B., and Charmillon, A. (2022). Stability Studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy. Antibiotics, 11.","DOI":"10.3390\/antibiotics11040458"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"dlae056","DOI":"10.1093\/jacamr\/dlae056","article-title":"Evaluation of the stability of ceftazidime\/avibactam in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy utilizing a national stability protocol framework","volume":"6","author":"Naicker","year":"2024","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-Rubio, B., Herrera-Hidalgo, L., de Alarc\u00f3n, A., Luque-M\u00e1rquez, R., L\u00f3pez-Cort\u00e9s, L.E., Luque, S., Guti\u00e9rrez-Urb\u00f3n, J.M., Fern\u00e1ndez-Polo, A., Guti\u00e9rrez-Valencia, A., and Gil-Navarro, M.V. (2023). Stability Studies of Antipseudomonal Beta Lactam Agents for Outpatient Therapy. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15122705"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1128\/AAC.46.8.2327-2332.2002","article-title":"Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units)","volume":"46","author":"Viaene","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/elps.202100275","article-title":"Liquid chromatographic method to follow-up ceftazidime and pyridine in portable elastomeric infusion pumps over 24 h","volume":"43","author":"Nguyen","year":"2022","journal-title":"Electrophoresis"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/ajhp\/55.7.683","article-title":"Drug stability and pyridine generation in ceftazidime injection stored in an elastomeric infusion device","volume":"55","author":"Stendal","year":"1998","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"212","DOI":"10.4212\/cjhp.v63i3.917","article-title":"Stability of commonly used antibiotic solutions in an elastomeric infusion device","volume":"63","author":"Walker","year":"2010","journal-title":"Can. J. Hosp. Pharm."},{"key":"ref_15","first-page":"275","article-title":"The mechanism of ceftazidime degradation in aqueous solutions","volume":"55","author":"Zajac","year":"1998","journal-title":"Acta Pol. Pharm."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1128\/AAC.02637-13","article-title":"How To Minimize Toxic Exposure to Pyridine during Continuous Infusion of Ceftazidime in Patients with Cystic Fibrosis?","volume":"58","author":"Bourget","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","unstructured":"(2020). Ceftazidimum pentahydricum et natrii carbonas ad iniectabile, monograph 2344. European Pharmacopoeia, 10.0, Council of Europe."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1136\/ejhpharm-2019-002093","article-title":"Ceftolozane-tazobactam in an elastomeric infusion device for ambulatory care: An in vitro stability study","volume":"27","author":"Raby","year":"2020","journal-title":"Eur. J. Hosp. Pharm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"dlab141","DOI":"10.1093\/jacamr\/dlab141","article-title":"Assessment of ceftolozane\/tazobactam stability in elastomeric devices and suitability for continuous infusion via outpatient parenteral antimicrobial therapy","volume":"3","author":"Jamieson","year":"2021","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.curtheres.2017.03.002","article-title":"Chemical Stability of Ceftolozane\/Tazobactam in Polyvinylchloride Bags and Elastomeric Pumps","volume":"84","author":"Terracciano","year":"2017","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"ref_21","unstructured":"Jamieson, C., Drummond, F., Ozolina, L., and Wilkinson, A.S. (2023, January 16). Stability Testing of Ceftazidime Solutions for Injection in Elastomeric Devices at 12 mg\/mL and 25 mg\/mL in 0.9% w\/v Saline for Safe Use in Outpatient Parenteral Antimicrobial Therapy (OPAT). BSAC OPAT Conference 2019, 11 December 2019. Available online: https:\/\/e-opat.com\/wp-content\/uploads\/2020\/01\/OPAT2019-CAZPoster-28Nov.pdf."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/ajhp\/zxy035","article-title":"Ceftazidime stability and pyridine toxicity during continuous i.v. infusion","volume":"76","author":"Jones","year":"2019","journal-title":"Am. J. Health-Syst. Pharm."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Negrier, L., Mena, A.M., Dupont, C., Gamache, P., Zimbril, J.O., Abdoune, Y., Karrout, Y., Odou, P., Genay, S., and Decaudin, B. (2024). The Infusion of Piperacillin\/Tazobactam with an Elastomeric Device: A Combined 24-H Stability Study and Drug Solution Flow Rate Analysis. Pharmaceuticals, 17.","DOI":"10.3390\/ph17081085"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/ajhp\/zxac122","article-title":"Antibiotic stability in portable elastomeric infusion devices: A systematic review","volume":"79","author":"Serrano","year":"2022","journal-title":"Am. J. Health-Syst. Pharm."},{"key":"ref_25","unstructured":"Committee for Medicinal Products for Human Use (2022). ICH Guideline M10 on Bioanalytical Method Validation and Study Sample Analysis Step 5, Committee for Medicinal Products for Human Use. EMA\/CHMP\/ICH\/172948\/2019."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/10\/966\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:49:49Z","timestamp":1760035789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/10\/966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":25,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["antibiotics14100966"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics14100966","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]}}}